Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anteris Technologies GlobalASX:AVR -1.34%45 Intrinsic Value: Projected FCF is A$-3.14 as of Sep. 02, 2026. GuruFocus rates ASX:AVR with a GF Score™ of 45/100. The stock has 6 warning signs investors should review. Among 412 Medical Devices & Instruments companies, Anteris Technologies Global ranks worse than 242718.2% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for Anteris Technologies Global's Intrinsic Value: Projected FCF or its related term are showing as below:
ASX:AVR's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.505 * Ranked among companies with meaningful Price-to-Projected-FCF only.
Anteris Technologies Global (ASX:AVR) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Anteris Technologies Global's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
11.75
/
-3.4483067378987
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anteris Technologies Global Intrinsic Value: Projected FCF Related Terms
Anteris Technologies Global Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Anteris Technologies Global's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anteris Technologies Global Intrinsic Value: Projected FCF Chart
ASX:AVR vs INMD, SIBN, BBNX: Intrinsic Value: Projected FCF Comparison
For the Medical Devices subindustry, Anteris Technologies Global's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anteris Technologies Global Price-to-Projected-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Anteris Technologies Global's Price-to-Projected-FCF falls into.
Anteris Technologies Global Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of A$-3.14 mean?
Anteris Technologies Global (ASX:AVR) has a Intrinsic Value: Projected FCF of A$-3.14 as of Sep. 02, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Anteris Technologies Global and its competitors. According to the industry distribution chart, Anteris Technologies Global ranks #999999 out of 412 companies in the Medical Devices & Instruments industry.
Is Anteris Technologies Global's Intrinsic Value: Projected FCF too high?
Anteris Technologies Global's current Intrinsic Value: Projected FCF is A$-3.14. Based on the distribution chart, Anteris Technologies Global ranks #999999 out of 412 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anteris Technologies Global has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's Intrinsic Value: Projected FCF compare to INMD and SIBN?
According to the Medical Devices & Instruments industry distribution chart, Anteris Technologies Global ranks #999999 out of 412 companies for Intrinsic Value: Projected FCF. This places Anteris Technologies Global in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.51, based on 412 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Anteris Technologies Global and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anteris Technologies Global's current Intrinsic Value: Projected FCF is A$-3.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (ASX:AVR) has a current Intrinsic Value: Projected FCF of A$-3.14. The current Intrinsic Value: Projected FCF is A$-3.14. Anteris Technologies Global's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Anteris Technologies Global (ASX:AVR), the current Intrinsic Value: Projected FCF is A$-3.14 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
45GF Score
Get the complete analysis for ASX:AVR
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVR has been successfully added to your 
